Micro Tempus

In 2015, Eric Lefkofsky, a founder of Groupon, started Tempus with the goal of bringing artificial intelligence to healthcare. The company's focus is on precision medicine, using AI to analyze large sets of clinical and molecular data to personalize patient treatment, initially for cancer. Tempus developed an operating system to make this multimodal data accessible and useful for physicians and researchers. The company established a significant footprint by connecting with a majority of academic medical centers and oncologists in the United States. This network provided a vast amount of de-identified data, which became a core asset for the company's AI-driven platform. Tempus's growth was accelerated through substantial funding rounds, reaching a valuation of over $8 billion by late 2020. To expand its capabilities and data, Tempus made a series of strategic acquisitions. In recent years, it acquired Deep 6 AI, a clinical trial recruitment platform, and Ambry Genetics, a genetic testing provider, for $600 million. Most recently, in August 2025, Tempus acquired Paige, an AI-powered digital pathology company, for $81.25 million, further enhancing its dataset with millions of digitized pathology slide images. These moves solidified Tempus's position in creating large-scale foundation models for oncology and advancing personalized medicine.